Mitochondria play a key role in cell death and its regulation. The permeabilization of the outer mitochondrial membrane which is mainly controlled by proteins of the BCL-2 family, is a key event that can be directly induced by p53 and results in the release of pro-apoptotic factors to the cytosol, such as cytochrome c, second mitochondria derived activator of caspases/direct inhibitor-of-apoptosis (IAP) binding protein with low p I (SMAC/Diablo), Omi serine protease (Omi/HtrA2), apoptosis inducing factor (AIF), or endonuclease G (Endo-G). Hence, the determination of subcellular localization of these proteins is extremely important to predict cell fate and elucidate the specifi c mechanism of apoptosis. Here we describe the procedures that can be used to study the subcellular location of different pro-apoptotic proteins to be used in basic cell biology and toxicology studies.
Introduction
Mitochondria are cellular organelles with important functions in cell life and death, acting as cellular powerhouses by producing energy to maintain cellular activity. However, mitochondria are also important checkpoints for cell fate decisions, playing a crucial role in programmed cell death (PCD) pathways. The permeabilization of the outer mitochondrial membrane (OMM) is a fundamental step in several tightly regulated pathways of cell death, allowing the release of proteins that are usually only present in the intermembrane space, and signaling cell death programs [ 1 ] . One of the best characterized types of cell death is apoptosis. Apoptotic signals may originate outside the cell (extrinsic pathway) or from any intracellular compartment (intrinsic pathway), constituting two distinct yet complementary apoptotic mechanisms. Both intrinsic and extrinsic stimuli may lead to OMM permeabilization.
The OMM is selectively permeable to solutes, and its permeability and integrity are regulated by proteins of the BCL-2 family [ 2 ] . This family includes pro-and anti-apoptotic members, depending on the presence of different BCL-2 homology (BH) domains in their structure, conferring different functions [ 3 ] . Anti-apoptotic proteins, such as BCL-2 and BCL-xL have four different BH domains-BH1234. Pro-apoptotic proteins such as BAX and BAK are also multi-domain proteins with three different BH domains-BH123. BH3-only proteins are pro-apoptotic proteins with only one BH domain and can exert their pro-apoptotic function either by facilitating or by activating BH123 proteins, which then initiate OMM permeabilization. Facilitators or de-repressors, such as BAD, interact with BH1234 proteins, dissociating them from sequestered pro-apoptotic proteins, which become free to promote OMM permeabilization. The activators, such as tBID (which results from the cleavage of BID by caspase-8), directly activate BH123 proteins, either by stimulating the translocation of Bad to the OMM, or by interacting with BAK. OMM permeabilization may occur through a Bax/Bak-mediated mechanism [ 4 ] or by the opening of the mitochondrial permeability transition pore (MPTP) in the inner mitochondrial membrane [ 5 ] . In the latter mechanism, opening of the MPTP can lead to mechanical rupture of the OMM to which pro-apoptotic protein release follows or instead to the recruitment of pro-apoptotic proteins to the OMM by causing mitochondrial depolarization [ 6 ] .
P53 is a redox-sensitive transcription factor with a broad range of actions, some of them related to survival and cell death [ 7 ] . In general, the tumor suppressor p53 exerts important roles in cell cycle progression and cell death coordinating multiple options for cellular response to genotoxic stress. p53 inhibits replication of the genome by blocking cell cycle progression at a G1/S check point in response to DNA damage [ 8 ] . In unstressed cells, p53 levels are low but its expression increase following stress signals acting through both transcription-dependent and -independent mechanisms to coordinate the appropriated cellular responses [ 9 ] . p53 activity depends on its ability to activate or repress gene transcription. Thus, p53 oscillates between latent and active sequencespecifi c DNA binding conformations and is differentially activated through posttranslational modifi cations including phosphorylation, acetylation and ubiquitination. On the other side, nonsequencespecifi c DNA binding may mediate other p53 actions [ 10 ] . In addition, p53 is also involved in mitochondrial-dependent cell death, collaborating in the execution of the apoptotic pathway. In this context, p53 undergoes a nuclear-cytoplasm-mitochondria traffi cking and western blotting and immunocytochemistry are usually performed to detect the presence of p53 in nuclear, cytoplasmic, and mitochondrial extracts isolated as described in this paper. The analysis of immunoreactive bands in nuclear fractions indicates whether nuclear translocation is occurring. The nuclear localization is critical for its transcriptional activity by activating genes that arrest cell growth and repair DNA damage. To further confi rm its transactivation function, evaluation of the expression of the transcription target genes of p53 such as PUMA, NOXA, BAX, BID, and DRAM is often useful [ 11 ] . As described above, the activity of the p53 gene product is regulated by posttranslational modifi cations. These modifi cations of p53 affect its stability and can be a potential mechanism to select the target genes conferring differential binding affi nity to the response elements. For example, acetylation infl uences p53 activity enhancing its transcriptional activity and can be detected using different acetyl-p53 antibodies available. Acetylation of p53 at carboxyl-terminal lysine residues enhances its transcriptional activity associated with cell cycle arrest and apoptosis. However, p53 acetylation at Lys-320/Lys-373/ Lys-382 is also required for transcription-independent functions involving BAX activation [ 12 ] . The phosphorylation of p53 at Ser15 and Ser20 following DNA damage can also be detected by immunoblotting to evaluate its transactivation function since this phosphorylation promotes p53 activation and stabilization reducing the interaction between p53 and its negative regulator, the oncoprotein murine double minute 2 (MDM2) [ 13 ] . In addition, phosphorylation at Ser392 infl uences transcriptional activation of p53 and regulates the oncogenic function of p53 [ 14 , 15 ] . MDM2 inhibits cytoplasmic retention of p53 by targeting it for ubiquitination and proteasomal degradation [ 16 ] . Some reports suggest not only that the cytoplasmic retention of p53 is able to repress autophagy [ 17 , 18 ] but also that this retention can be mediated by acetylation since p53 acetylation reduces its ubiquitination status [ 19 ] . Although the precise molecular mechanisms behind this remain unclear, p53 deacetylases may be upregulated to mediate ubiquitination and degradation of p53 [ 20 ] . Because of this, the immunoblot analysis of cytoplasmic extracts can reveal whether p53 is accumulated in cytoplasm and can help to reveal the function of p53 in a specifi c context. p53 can promote cell death independently of transcription by two different mechanisms, each of which assigned to a specifi c localization of the protein: cytosol or mitochondrial. Both modes of action converge in the permeabilization of the OMM via activation of the pro-apoptotic proteins BAX or BAK. In fact, cytosolic p53 can directly activate BAX and thereby induce apoptosis [ 21 ] . On the other hand, in response to a broad spectrum of apoptotic stimuli, a fraction of p53 translocates to mitochondria and triggers a direct mitochondrial p53 death program [ 22 ] . For this, p53 physically interacts with the BCL-2 family member proteins BCL-xL and BCL-2 antagonizing their anti-apoptotic function and inducing OMM permeabilization [ 23 ] . Furthermore, mitochondrial p53 directly promotes the pro-apoptotic activities of BAX and directly induces BAK oligomerization [ 24 ] . p53 also interacts with the antioxidant enzyme superoxide dismutase 2 (SOD2) leading to a reduction of its superoxide scavenging activity, and a subsequent decrease of mitochondrial membrane potential which contributes to the induction of pro-apoptotic mitochondrial alterations [ 25 ] . Surprisingly, p53 is released from mitochondria mediating a retrograde signaling pathway to the nucleus [ 26 ] . Therefore, the study of the subcellular localization of p53, its posttranslational modifi cations and the levels of p53-related/-targeted proteins are crucial to examine the p53 pathway and elucidate its particular role.
As described above, OMM permeabilization resulting from stress stimuli can result in simultaneous release of pro-apoptotic factors that are normally limited to the mitochondrial intermembrane or intercristae space, including cytochrome c, apoptosisinducing factor (AIF), endonuclease G (endoG), Smac/Diablo, and Omi/HtrA2 [ 27 ] . Cytochrome c was fi rst identifi ed as being involved in mitochondrial bioenergetics, essential for the ATP production by oxidative phosphorylation, and later to apoptosis. Following the release of cytochrome c from the intermembrane space, it binds to Apoptotic protease activating factor 1 (APAF-1) and dATP [ 28 ] , forming the apoptosome complex and initiating cell death with the activation of caspase-9 and consequent triggering of caspase cascade [ 29 ] . The second mitochondrial-derived activator of caspase (Smac), also known as direct IAP-binding protein with a low p I (Diablo) [ 29 ] , resides in mitochondria in a mature form, and is released during apoptosis, which promotes caspase-dependent apoptosis by controlling the activity of inhibitor of apoptosis protein (IAP). Omi is a serine protease, which can be released from mitochondrial intermembrane space into cytoplasm, upon apoptotic insult. Omi cleaves both IAPs and cytoskeletal proteins, contributing to apoptosis in caspase-dependent and independent manners [ 30 ] .
Independently of caspase activation, cell death can occur with the release of endoG and AIF. EndoG is also localized in intermembrane space bound to the inner membrane. Due to mitochondrial membrane potential loss, the mature EndoG is translocated to the nucleus and initiates oligonucleosomal DNA fragmentation. EndoG can regulate several mitochondrial enzymes expression, such as complex I (ND1 and ND2), complex IV (COX2), and complex V (ATPase6) [ 30 ] (Fig. 1 ) . The AIF is a fl avoprotein harboring NADH oxidase activity. Initially, the AIF was identifi ed as a pro-apoptotic protein, inducing a type of programmed cell death independently of caspases activation. When AIF is added to purifi ed nuclei extracts in a cell free system, chromatin condensation and largescale DNA fragmentation to ∼50 kbp fragments occurs [ 31 ] . Those effects were observed in intact cells after diverse apoptotic stimuli and also in models of retinal degeneration, brain damage induced by hypoglycemia or ischemia, or myocardial infarction [ 32 ] .
The AIF protein is encoded by a nuclear gene, synthesized in the cytoplasm and transported to mitochondria by the general import pathway, due to the mitochondrial localization sequence (MLS) in the precursor protein. Once in the mitochondrial intermembrane space, the MLS is proteolytically cleaved, the protein refolds and incorporates fl avin adenine dinucleotide (FAD) cofactor, generating the mature protein. The oxidoreductase activity, dependent of the presence of prosthetic group, is not critical for the apoptogenic effect of AIF but the structural parts of the oxidoreductase domain are necessary to the DNA biding [ 31 ] . Fig. 1 Intrinsic apoptotic pathway. The intrinsic or mitochondrial apoptotic pathway, initiates with mitochondrial membrane permeabilization, which may result from p53 signaling, with formation of different pores in mitochondrial membrane, such as Bax/Bak or mitochondrial permeability transition pore (MPTP), in the latter case by leading to OMM rupture or by triggering pro-apoptotic protein translocation to mitochondria following mitochondrial depolarization. Consequently, the release of apoptotic factors to cytosol, including cytochrome c, second mitochondria derived activator of caspases/direct inhibitor-of-apoptosis binding protein with low p I (SMAC/Diablo), Omi serine protease (Omi/HrtA2), endonuclease G (endoG), and apoptosis-inducing factor (AIF), occurs. The released cytochrome c reacts with deoxy ATP (dATP) and apoptotic protease activating factor 1 (APAF-1), leading to apoptosome formation. The apoptosome recruits procaspase-9, activating the initiator caspase-9 and caspase cascade begins A decrease in AIF enzymatic activity or a decrease in AIF expression results in decreased oxidative phosphorylation and increased free radicals generation [ 33 ] . On the other hand and depending on cell type and on the cell death stimuli, AIF protein is involved in programmed cell death. The basic mechanism of AIF-induced cell death consists in AIF release from the mitochondrial intermembrane space to the cytosol and then on its translocation to the nucleus. Once in the nucleus, AIF binds to DNA induces chromatin condensation and large-scale DNA fragmentation. The nuclear apoptosis induced by AIF requires a direct interaction of AIF with DNA [ 34 ] . In the cytosol, AIF also promotes a decrease in mitochondrial ΔΨ and release of cytochrome c and further AIF release from mitochondria, promoting a positive feedback amplifi cation loop [ 31 , 32 ] . In order to be released from the mitochondrial intermembrane space, AIF must be cleaved in a specifi c region in order to release the protein binding to the mitochondrial inner membrane. This cleavage is performed by proteases such as calpains and cathepsins that may have access to the mitochondrial intermembrane space during apoptotic stimuli and require the presence of calcium. The truncated AIF (tAIF) is then free to execute its caspase-independent apoptotic action. An interesting aspect is the fact that binding of AIF to DNA induces largescale DNA fragmentation, but AIF itself does not possess DNAse activity. Thus, it has been proposed that the DNA-degrading capacity of AIF could be due to the recruitment of downstream nucleases, such as cyclophilin A (CypA) [ 35 , 36 ] .
In this chapter, we describe the material and the methods followed by us and other authors to study the pro-apoptotic protein traffi cking to and from mitochondria: immunoblotting performed with different cellular fractions and immunocytochemistry using the antibodies described in Table 1 . Immunocytochemical approaches can be used to study subcellular localization of proapoptotic factors described in this chapter. To evaluate their mitochondrial localization, co-localization assays using antibodies constitute an effective alternative (Fig. 2 ) . One option is to develop an immunocytochemistry using a secondary antibody conjugated with a fl uorochrome such as FITC and to label mitochondria using mitochondria-selective probes such as MitoTracker Red. Another option consists in a double immunofl uorescence assay using a mixture of two primary antibodies, for example one against the mitochondrial marker TOM20 and the other against the desired pro-apoptotic protein, using their respective secondary antibodies which have to be raised in different species and conjugated with two different fl uorochromes (e.g., FITC-conjugated against rabbit and Texas Red-conjugated against mouse). 
Nuclear, Mitochondrial, and Cytosolic Fraction Isolation from Cultured Cells
5. Prolong Gold antifade medium with DAPI (P36935; Invitrogen) or without DAPI (P36934; Invitrogen) and nail polish.
Western Blotting

Immunoprecipitation 2.4 Immunocytochemistry
3 Methods 
Supplement buffer
5.
Centrifuge between 300 and 400 × g for 5 min at 4 °C in order to collect all cells without damaging membrane integrity.
6. Aspirate the supernatant and rinse the cell pellet with 2 ml of PBS. Perform again the centrifugation step, discard the supernatant and resuspend the pellet in 1 ml of complete buffer A. Incubate for 15 min on ice.
Homogenize cells in a Potter-Elvehjem homogenizer with a
Tefl on pestle (30-40 strokes), or alternatively pass cell suspension through a 25 G needle ten times using a 1 ml syringe. This procedure should also be performed on ice.
8. Centrifuge the cellular suspension at 720 × g for 5 min at 4 °C. Remove the supernatant (containing mitochondrial and cytosolic fractions) and keep it on ice.
9. Resuspend the nuclear pellet again in 1 ml of complete buffer A. Homogenize the pellet again in a Potter-Elvehjem homogenizer with a Tefl on pestle, or alternatively pass through a 25 G needle. Centrifuge again at 720 × g for 10 min at 4 °C. Discard the supernatant and resuspend the pellet in 0.5 ml of complete buffer B and pour the nuclear suspension on the complete buffer C. Centrifuge at 1,430 × g for 5 min at 4 °C. Remove the supernatant and discard it. Resuspend the nuclear pellet in 50 μl of nuclear buffer supplemented with 300 mM of NaCl. Homogenize the nuclear pellet passing nuclear suspension through a 27 G needle ten times using a 0.5 ml syringe. Store at −80 °C until further analysis.
10. Centrifuge the supernatant collected in step 8 at 14,000 × g for 10 min at 4 °C. Resuspend the pellet (mitochondrial fraction) in 50 μl of buffer 1 and store at −80 °C until further analysis.
11. Collect the supernatant (containing the cytosolic fraction) and centrifuge in an ultracentrifuge at 100,000 × g for 30 min at
Nuclear, Mitochondrial, and Cytosolic Fraction Isolation from Cells in Culture
4 °C. Discard the pellet (containing the membrane fractions) and concentrate the supernatant (containing the cytosolic fraction) by lyophilization or by tangential fl ow fi ltration. Store at −80 °C until further analysis be performed ( see Note 4 ).
In Fig. 3 , a fl owchart outlining the isolation procedure is presented 1. Determine protein content of all fractions by standard procedures such as the Bradford or the BCA method using 5 μl of aliquot.
2. Mix the samples with the appropriated volume of Laemmli buffer (1:1). 3. Centrifuge 1 min at 16,000 × g and discard the supernatant fraction.
4. Add 1 ml of IP buffer I to the pellet and mix the sample on an oscillatory shaker for 20 min at 4 °C.
5.
Centrifuge for 1 min at 16,000 × g and discard the supernatant fraction.
Enzymatic Immunodetection
Immunoprecipitation
1. Mount coverslips on glass slides using Prolong Gold antifade medium (P36934; Invitrogen). If nuclear labeling is desired, use Prolong Gold antifade medium with DAPI (P36935; Invitrogen).
2. Allow to dry overnight, seal with nail polish, and store at −80 °C until analysis under a confocal microscope (LSM 510Meta; Zeiss).
Notes
1. Alternatively to the use of β-mercaptoethanol in Western Blot sample preparation, dithiothreitol (DTT) can be used in the same proportion.
2. In order to have enough protein for the different cellular fractions, it is often necessary to start with large amount of cells, especially for large volume cells. Optimization process for cell density is required.
3. If the incubation medium is saved in order to collect fl oating cells, it can be used to inhibit the trypsin.
4.
It is advisable to test the purity of each sample using specifi c antibodies for each fraction. For example, one strategy involves cross-labeling samples from different fractions with antibodies against a particular histone (nuclear marker), the voltagedependent anion channel (VDAC) or TOM20 (mitochondrial markers), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, a cytosolic marker).
5.
Choose the percentage of the gel to be used according to the molecular weight of proteins of interest. In general: 4-5 % gels: >250 kDa; 7.5 % gels: 250-120 kDa; 10 % gels: 120-40 kDa; 13 % gels: 40-15 kDa; 15 % gels: <20 kDa.
6. Apply 5-25 μg total protein of sample to each well of a 0.75-1.0 mm thick gel. For thicker gels (1.5 mm thick), apply up to 25-40 μg in each well.
7.
For proteins smaller than 20 kDa, transfer proteins from gel to PVDF membrane at 350 mA for 1 h in transfer buffer. For proteins larger than 120 kDa, transfer to PVDF membrane at 350 mA for 140 min in transfer buffer supplemented with 0.05 % SDS.
8. Some antibodies require the use of BSA (1-5 %) as a blocking agent. Read the vendor's instructions before following the method.
9. All incubation and washing steps are carried out while gently shaking.
Mounting Coverslips
10. Alternatively, regular medium without phenol red or Krebs medium can be used, to avoid interferences with the probe's fl uorescence.
11. Unspecifi c binding of the antibodies can be also blocked with 10 % serum from the species in which the secondary antibody was raised.
